Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Kalorama report focuses on global Alzheimer’s treatments

Kalorama Information : 29 August, 2008  (Company News)
A new report from Kalorama Information entitled ‘World Alzheimer's Disease Market (Incidence, Treatments, Key Companies, Pipeline and Trends)’ highlights that several patents for Alzheimer’s treatments are approaching expiration, and developers are working on innovations in anticipation of impending generic competition.
Demand for Alzheimer’s treatments has surged over the past decade – sales grew a healthy 17.3 percent annually from 2005 to 2007. Though growth is expected to continue at a strong 6.7 percent annual rate through 2012, this is significantly slower than before, and can be attributed to a sudden drop in growth after 2010 as a number of drugs near patent expirations and generic companies prepare to launch equivalent products. Teva, Dr Reddy’s, Ranbaxy, Mylan, Barr, Sun Pharma, Genpharm, Lupin, and Wockhardt are all expected to have generic versions of some of the world’s largest Alzheimer’s drugs on the market by 2010.

“Eisai’s Aricept, which has the lion’s share of the market, is a prime target for generic competition,” notes Mellisa Elder, Kalorama Information’s pharmaceutical analyst. “Its patent is still enforceable as it was granted in 1990. But Eisai has been fighting with Teva, Mutual and United Research Labs, and more court proceedings are expected.”

To counter the imminent generic onslaught, several developers are offering promising innovative treatments in all phases of development, including Eisai’s sustained release formulation of Aricept SR which is in phase III development. The number of new drugs in development has increased, from about 20 in 2005 to almost 60 in 2007.

Kalorama Information’s report ‘World Alzheimer's Disease Market (Incidence, Treatments, Key Companies, Pipeline and Trends)’ provides a worldwide overview of this multi-billion dollar market. A market analysis by product and region, products in development and forecasts through 2012 are included, along with a competitive analysis and key company profiles.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 ProHealthServiceZone.com
Netgains Logo